Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

{
  "signal_id": "1a6b5652-b550-cffd-481f-b8dec5b97d5e",
  "signal_type": "news",
  "signal_subtype": "invests_into",
  "detected_at": "2026-08-13T11:15:58+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "url": "https://www.manilatimes.net/2026/08/13/tmt-newswire/globenewswire/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates/2404708/amp",
    "title": "Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times",
    "excerpt": "Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company's proprietary Helicon TM platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties Ended the second quarter with a strong financial position with $1.1B in cash, cash equivalents and marketable securities, following completion of $770.5M initial public offering and other transactions, expected to fund operations into 2030 CAMBRIDGE, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today reported financial results and business updates for the second quarter ended June 30, 2026. \"This quarter marked meaningful progress toward our long-term vision as we continued advancing zolucatetide across multiple Wnt/β-catenin-driven diseases, including toward planned registrational development in desmoid tumors, while also extending the reach of our Helicon™ platform through our strategic research collaboration with Regeneron...",
    "summary": "Regeneron made a $125 million equity investment and upfront payment into Parabilis Medicines as part of a strategic research collaboration.",
    "location": "CAMBRIDGE, Mass.",
    "planning": false,
    "image_url": "https://manilatimes.net/manilatimes/uploads/images/2026/08/13/1175534.png",
    "confidence": 0.9,
    "published_at": "2026-08-13T11:15:58Z",
    "location_data": [
      {
        "city": "Cambridge",
        "state": "Massachusetts",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company's proprietary Helicon TM platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties",
    "amount_normalized": 125000000,
    "financing_type_tags": [
      "ipo"
    ],
    "related_company_name": "Parabilis Medicines",
    "related_company_domain": "parabilismed.com",
    "financing_type_normalized": "post_ipo"
  }
}

curl https://signals.autobound.ai/v1/signals/1a6b5652-b550-cffd-481f-b8dec5b97d5e \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"regeneron.com","limit":20}'